SG11202000747VA - Anti-cd137 antibodies - Google Patents

Anti-cd137 antibodies

Info

Publication number: SG11202000747VA
Authority: SG; Singapore
Prior art keywords: antibodies
Prior art date: 2017-08-01

Application number

SG11202000747VA

Other languages

English (en)

Inventor

Christopher Carl Frye

Michael Dewain Kalos

Helen Kotanides

Stephanie Lynn Sandefur

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-01

Filing date

2018-07-25

Publication date

2020-02-27

2018-07-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-02-27 Publication of SG11202000747VA publication Critical patent/SG11202000747VA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11202000747VA 2017-08-01 2018-07-25 Anti-cd137 antibodies SG11202000747VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762539687P	2017-08-01	2017-08-01
PCT/US2018/043632 WO2019027754A1 (en)	2017-08-01	2018-07-25	ANTI-CD137 ANTIBODIES

Publications (1)

Publication Number	Publication Date
SG11202000747VA true SG11202000747VA (en)	2020-02-27

Family

ID=63165504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202000747VA SG11202000747VA (en)	2017-08-01	2018-07-25	Anti-cd137 antibodies

Country Status (22)

Country	Link
US (1)	US10906983B2 (es)
EP (2)	EP3661544B1 (es)
JP (2)	JP6743320B1 (es)
KR (2)	KR20210158420A (es)
CN (1)	CN111182919B (es)
AU (2)	AU2018311804B2 (es)
BR (1)	BR112020001441A2 (es)
CA (2)	CA3071383C (es)
CL (1)	CL2020000233A1 (es)
CO (1)	CO2020001050A2 (es)
CR (1)	CR20200042A (es)
DO (1)	DOP2020000020A (es)
EA (1)	EA202090204A1 (es)
EC (1)	ECSP20007663A (es)
ES (1)	ES2912651T3 (es)
IL (1)	IL272349B1 (es)
JO (1)	JOP20200016B1 (es)
MA (1)	MA49749A (es)
MX (1)	MX2020001351A (es)
PH (1)	PH12020500225A1 (es)
SG (1)	SG11202000747VA (es)
WO (1)	WO2019027754A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11512134B2 (en)	2017-08-01	2022-11-29	Eli Lilly And Company	Anti-CD137 antibodies
EP3652209A2 (en)	2017-07-11	2020-05-20	Compass Therapeutics LLC	Agonist antibodies that bind human cd137 and uses thereof
MA49749A (fr) *	2017-08-01	2021-03-24	Lilly Co Eli	Anticorps anti-cd137
US11718679B2 (en)	2017-10-31	2023-08-08	Compass Therapeutics Llc	CD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en)	2017-11-20	2023-12-26	Compass Therapeutics Llc	CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CA3094998C (en) *	2018-03-23	2023-05-09	Eli Lilly And Company	Anti-cd137 antibodies for combination with anti-pd-1 antibodies
CN112020517A (zh) *	2018-03-23	2020-12-01	伊莱利利公司	用于与抗pd-l1抗体组合的抗cd137抗体
JP7090204B2 (ja) *	2018-07-19	2022-06-23	イーライリリーアンドカンパニー	免疫チェックポイントを標的とする二重特異性抗体
JP2022530026A (ja)	2019-04-24	2022-06-27	ハイデルベルクファルマリサーチゲゼルシャフトミットベシュレンクテルハフツング	アマトキシン抗体薬物複合体及びその使用
BR112021026309A2 (pt) *	2019-06-26	2022-06-07	Ap Biosciences Inc	Anticorpos para ativação de células t
TW202144395A (zh) *	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
WO2022111571A1 (zh)	2020-11-25	2022-06-02	上海君赛生物科技有限公司	肿瘤浸润淋巴细胞培养基及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7651686B2 (en) *	2001-10-09	2010-01-26	Mayo Foundation For Medical Education And Research	Enhancement of immune responses by 4-1bb-binding agents
US7288638B2 (en)	2003-10-10	2007-10-30	Bristol-Myers Squibb Company	Fully human antibodies against human 4-1BB
EP2614082B1 (en)	2010-09-09	2018-10-03	Pfizer Inc	4-1bb binding molecules
AU2016219772A1 (en) *	2015-02-22	2017-09-21	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind CD137
GB201619648D0 (en) *	2016-11-21	2017-01-04	Alligator Bioscience Ab	Novel antibodies and uses thereof
MA49749A (fr)	2017-08-01	2021-03-24	Lilly Co Eli	Anticorps anti-cd137

2018
- 2018-07-25 MA MA049749A patent/MA49749A/fr unknown
- 2018-07-25 CN CN201880064332.2A patent/CN111182919B/zh active Active
- 2018-07-25 US US16/497,493 patent/US10906983B2/en active Active
- 2018-07-25 WO PCT/US2018/043632 patent/WO2019027754A1/en unknown
- 2018-07-25 ES ES18752950T patent/ES2912651T3/es active Active
- 2018-07-25 CA CA3071383A patent/CA3071383C/en active Active
- 2018-07-25 KR KR1020217041897A patent/KR20210158420A/ko not_active Application Discontinuation
- 2018-07-25 KR KR1020207002814A patent/KR102344620B1/ko active IP Right Grant
- 2018-07-25 CR CR20200042A patent/CR20200042A/es unknown
- 2018-07-25 CA CA3146758A patent/CA3146758A1/en active Pending
- 2018-07-25 JP JP2020505392A patent/JP6743320B1/ja active Active
- 2018-07-25 AU AU2018311804A patent/AU2018311804B2/en active Active
- 2018-07-25 SG SG11202000747VA patent/SG11202000747VA/en unknown
- 2018-07-25 JO JOP/2020/0016A patent/JOP20200016B1/ar active
- 2018-07-25 MX MX2020001351A patent/MX2020001351A/es unknown
- 2018-07-25 EP EP18752950.8A patent/EP3661544B1/en active Active
- 2018-07-25 EA EA202090204A patent/EA202090204A1/ru unknown
- 2018-07-25 IL IL272349A patent/IL272349B1/en unknown
- 2018-07-25 EP EP22159268.6A patent/EP4070811A1/en not_active Withdrawn
- 2018-07-25 BR BR112020001441-9A patent/BR112020001441A2/pt unknown
2020
- 2020-01-29 CO CONC2020/0001050A patent/CO2020001050A2/es unknown
- 2020-01-29 CL CL2020000233A patent/CL2020000233A1/es unknown
- 2020-01-30 PH PH12020500225A patent/PH12020500225A1/en unknown
- 2020-01-31 EC ECSENADI20207663A patent/ECSP20007663A/es unknown
- 2020-01-31 DO DO2020000020A patent/DOP2020000020A/es unknown
- 2020-07-29 JP JP2020128427A patent/JP7257364B2/ja active Active
2021
- 2021-12-02 AU AU2021277707A patent/AU2021277707A1/en active Pending

Also Published As

Publication number	Publication date
JP2020527356A (ja)	2020-09-10
AU2018311804B2 (en)	2021-09-02
WO2019027754A1 (en)	2019-02-07
US10906983B2 (en)	2021-02-02
CA3146758A1 (en)	2019-02-07
EP3661544B1 (en)	2022-04-13
ES2912651T3 (es)	2022-05-26
JOP20200016A1 (ar)	2020-01-28
CN111182919A (zh)	2020-05-19
MA49749A (fr)	2021-03-24
KR102344620B1 (ko)	2022-01-03
KR20210158420A (ko)	2021-12-30
AU2018311804A1 (en)	2020-02-13
IL272349A (en)	2020-03-31
IL272349B1 (en)	2024-05-01
CA3071383C (en)	2022-04-12
EP4070811A1 (en)	2022-10-12
CO2020001050A2 (es)	2020-02-18
EP3661544A1 (en)	2020-06-10
CL2020000233A1 (es)	2020-07-31
US20200377607A1 (en)	2020-12-03
JP2020182492A (ja)	2020-11-12
BR112020001441A2 (pt)	2020-08-04
KR20200023439A (ko)	2020-03-04
CN111182919B (zh)	2023-07-07
CA3071383A1 (en)	2019-02-07
JP6743320B1 (ja)	2020-08-19
AU2021277707A1 (en)	2021-12-23
MX2020001351A (es)	2020-03-09
PH12020500225A1 (en)	2020-11-09
JP7257364B2 (ja)	2023-04-13
JOP20200016B1 (ar)	2022-10-30
CR20200042A (es)	2020-03-03
DOP2020000020A (es)	2020-02-28
EA202090204A1 (ru)	2020-05-22
ECSP20007663A (es)	2020-06-30

Publication	Publication Date	Title
IL268517A (en)	2019-09-26	Anti-tigit antibodies
IL272227A (en)	2020-03-31	ANTI-TIGIT antibodies
ZA201905966B (en)	2023-03-29	Anti-lag3 antibodies
LT3625259T (lt)	2024-07-10	Anti-sirpalfa antikūnai
IL267797B1 (en)	2023-03-01	Anti-gpc3 antibody
GB201709808D0 (en)	2017-08-02	Antibodies
IL272349A (en)	2020-03-31	ANTI-CD137 antibodies
GB201601073D0 (en)	2016-03-02	Antibodies
GB201811404D0 (en)	2018-08-29	Anti-CD137 Antibodies
IL273393A (en)	2020-05-31	New epsilon anti-CD3 antibodies
SG10201914130VA (en)	2020-03-30	GARP-TGF-β ANTIBODIES
ZA202002141B (en)	2023-01-25	Anti-transthyretin antibodies
GB201720970D0 (en)	2018-01-31	Antibodies
ZA202103456B (en)	2023-01-25	Anti-alpha-synuclein antibodies
IL273529A (en)	2020-05-31	Anti-PACAP antibody
IL271067A (en)	2020-01-30	Anti-trkb antibodies
GB201711785D0 (en)	2017-09-06	Antibodies
GB201717006D0 (en)	2017-11-29	Anti-OPG antibodies
GB201709818D0 (en)	2017-08-02	Antibodies
GB201703071D0 (en)	2017-04-12	Antibodies
GB201701416D0 (en)	2017-03-15	Anti-OPG antibodies
GB201709592D0 (en)	2017-08-02	Antibody